Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery

Experimental and Clinical Cardiology

Volumn 13, Issue 4, 2008, Pages 171-174

  Krivoy, Norberto ^a,b   Adler, Zvi ^c   Saloma, Ronen ^a   Hawadie, Ashraf ^d   Azzam, Zaher S ^b,d  

^a Clinical Pharmacology Institute   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Cardiovascular Surgery   (Israel)

^d NONE   (Israel)

Author keywords

C reactive protein; Coronary surgery; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; HUMAN; INFLAMMATION; INTRAOPERATIVE PERIOD; LOADING DRUG DOSE; LONG TERM CARE; OPEN HEART SURGERY; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 63449129652     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol, screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
2. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction. J Am Coll Cardiol 2006;47:962-8.
3. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
4. Venogopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role. Curr Opinion Nephrol Hypert 2005;14:33-7.
5. Yasojima K, Schwab C, McGeer EG. Generation of C-reactive protein and complement components in atherosclerosis plaques. Am J Pathol 2001;158:1039-51.
6. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996;156:4815-20.
7. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-2.
8. Visushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7.
9. Pepys MB, Hirshfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.
10. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
11. Karaca I, Ilkay E, Akbulut M, et al. Atorvastatin effects C-reactive protein levels in patients with coronary artery disease. Curr Med Res Opin 2003;19:187-91.
12. Wassmann S, Nickenig G. Improvement of endothelial function by HMG-CoA reductase inhibitors. Drug News Perspect 2002;15:85-92.
13. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vase Biol 2002;22:300-5.
14. Lazar HL, Bao Y, Zhang Y, Bernard SA. Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 2003;125:1037-42.
15. Pan W, Pinter T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110(Suppl 2):45-9.
16. Clark LL, Ikonomidis JS, Crawford FA Jr, Crumbly A 3rd, Kratz JM, Stroud MR. Preoperative statin treatment is associated with reduced post operative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective cohort study. J Thorac Cardiovasc Surg 2006;131:679-85.
17. Chello M, Patti G, Candure D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-7.
18. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-61.
19. Buffon A, Liouzzo G, Biasucci LM. Pre-procedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
20. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60.
21. Skrak P, Kovacikova L, Kunovsky P. Procalcitonin, neopterin and C-reactive protein after pediatric cardiac surgery with cardiopulmonary bypass. Bratisl Lek Listy 2007;108:501-5.
22. Hilgendorf A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003;41:397-401.
23. Wong S, Schwartz RC, Pestka JJ. Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization. Toxicology 2001;161:139-49.
24. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
25. Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Cite Res 2005;96:714-6.
26. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
27. Aouifi A, Piriou V, Blanc P, et al. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br J Anaesth 1999;83:602-7.
28. Lazar H. Should all patients receive statins before cardiac surgery: Are more data necessary? J Thorac Cardiovasc Surg 2006;131:520-2.
29. Gaudino M, Nasso G, Andreotti F, et al. Preoperative C-reactive protein level and outcome following coronary surgery. Eur J CardioThorac Surg 2002;22:521-6.
30. Ehl S, Gehring B, Pohlandt F. A detailed analysis of changes in serum C-reactive protein levels in neonates treated for bacterial infection. Eur J Pediatr 1999;158:238-42.